- Home
- CLH vs NBIX Comparison
CLH vs NBIX Comparison
Compare CLH & NBIX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CLH
- NBIX
- Stock Information
- Founded
- CLH 1980
- NBIX 1992
- Country
- CLH United States
- NBIX United States
- Employees
- CLH N/A
- NBIX N/A
- Industry
- CLH Environmental Services
- NBIX Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- CLH Industrials
- NBIX Health Care
- Exchange
- CLH Nasdaq
- NBIX Nasdaq
- Market Cap
- CLH 14.0B
- NBIX 13.7B
- IPO Year
- CLH 1987
- NBIX 1996
- Fundamental
- Price
- CLH $246.34
- NBIX $145.88
- Analyst Decision
- CLH Strong Buy
- NBIX Buy
- Analyst Count
- CLH 8
- NBIX 22
- Target Price
- CLH $266.75
- NBIX $164.81
- AVG Volume (30 Days)
- CLH 335.9K
- NBIX 926.1K
- Earning Date
- CLH 02-19-2025
- NBIX 02-05-2025
- Dividend Yield
- CLH N/A
- NBIX N/A
- EPS Growth
- CLH 15.34
- NBIX 97.40
- EPS
- CLH 7.68
- NBIX 3.73
- Revenue
- CLH $5,797,005,000.00
- NBIX $2,242,800,000.00
- Revenue This Year
- CLH $10.09
- NBIX $27.18
- Revenue Next Year
- CLH $6.03
- NBIX $17.92
- P/E Ratio
- CLH $32.11
- NBIX $39.13
- Revenue Growth
- CLH 8.37
- NBIX 25.72
- 52 Week Low
- CLH $167.28
- NBIX $110.95
- 52 Week High
- CLH $267.11
- NBIX $157.98
- Technical
- Relative Strength Index (RSI)
- CLH 63.50
- NBIX 70.01
- Support Level
- CLH $227.01
- NBIX $138.66
- Resistance Level
- CLH $231.17
- NBIX $144.24
- Average True Range (ATR)
- CLH 4.60
- NBIX 3.32
- MACD
- CLH 2.35
- NBIX 0.23
- Stochastic Oscillator
- CLH 94.46
- NBIX 96.20
About CLH Clean Harbors Inc.
Clean Harbors Inc is an environmental and industrial services provider. It provides parts cleaning and related environmental services to commercial, industrial, and automotive customers. Its business segments are Environmental Services and Safety-Kleen Sustainability Solutions. The company generates the majority of its revenues from the Environmental Services segment.
About NBIX Neurocrine Biosciences Inc.
Neurocrine Biosciences Inc is a research-based pharmaceutical company advancing drug candidates in the central nervous system and endocrine-related categories. The company's three late stage clinical programs are elagolix which is hormone releasing antagonist for women's health, opicapone which is an inhibitor for parkinson's patients, and ingrezza for tourette syndrome.